Taysha Gene Therapies (TSHA) Accounts Payables (2020 - 2026)

Taysha Gene Therapies has disclosed Accounts Payables across 7 years of filings, most recently posting $4.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.6 million, up 5.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (up 5.5% YoY), and the FY2025 annual result was $6.3 million, up 74.69% from the prior year.
• Accounts Payables came in at $4.6 million for Q1 2026 at Taysha Gene Therapies, down from $6.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $24.0 million in Q2 2022 to a low of $3.6 million in Q4 2024.
• The 5-year median for Accounts Payables is $7.7 million (2025), against an average of $9.5 million.
• Across the five-year window, Accounts Payables surged 438.75% in 2022 and sank 59.08% in 2023, its largest moves.
• Taysha Gene Therapies' Accounts Payables stood at $10.9 million in 2022, then plunged by 41.84% to $6.4 million in 2023, then plunged by 43.58% to $3.6 million in 2024, then soared by 74.69% to $6.3 million in 2025, then decreased by 27.27% to $4.6 million in 2026.
• The last three Accounts Payables figures came in at $4.6 million (Q1 2026), $6.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.